Early C-reactive protein reduction predicts survival in real-world extensive-stage small cell lung cancer treated with first-line adebrelimab-based immunotherapy

BackgroundExtensive-stage small cell lung cancer (ES-SCLC) remains an aggressive malignancy with limited biomarkers for predicting outcomes in real-world settings. While baseline systemic inflammation correlates with prognosis, the role of longitudinal inflammation dynamics during PD-L1 inhibitor-ba...

Szczegółowa specyfikacja

Opis bibliograficzny

Główni autorzy:	Jian Wang, Xueli Zhang, Qijia Gao, Jianxin Chen
Format:	Artigo
Język:	Inglês
Wydane:	Frontiers Media S.A. 2025-11-01
Seria:	Frontiers in Oncology
Hasła przedmiotowe:	extensive-stage small cell lung cancer C-reactive protein real-world evidence adebrelimab prognostic biomarker
Dostęp online:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1709336/full
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!